Can Fluidigm Corporation (FLDM)’s Tomorrow Be Different? The Stock Increases Again

February 15, 2018 - By Vivian Currie

Investors sentiment increased to 1.58 in Q3 2017. Its up 0.37, from 1.21 in 2017Q2. It is positive, as 7 investors sold Fluidigm Corporation shares while 17 reduced holdings. 8 funds opened positions while 30 raised stakes. 32.41 million shares or 37.16% more from 23.63 million shares in 2017Q2 were reported.
Acadian Asset Mgmt Ltd holds 0% or 86,866 shares in its portfolio. 54,400 are owned by California Public Employees Retirement System. Adage Cap Gru Ltd Limited Liability Company holds 1.83 million shares. Citigroup holds 97 shares. Rhumbline Advisers holds 0% or 31,189 shares in its portfolio. 110,326 were reported by Connor Clark And Lunn Mngmt Limited. Tower Research Cap Limited Liability Company (Trc) reported 11,639 shares or 0% of all its holdings. 143,572 are owned by Bridgeway Cap Mngmt Incorporated. Deutsche Financial Bank Ag stated it has 0% in Fluidigm Corporation (NASDAQ:FLDM). D E Shaw & Company Inc accumulated 0% or 151,651 shares. Renaissance Technology Lc, New York-based fund reported 670,600 shares. State Board Of Administration Of Florida Retirement System has invested 0% in Fluidigm Corporation (NASDAQ:FLDM). Interest Grp Inc Inc reported 0% in Fluidigm Corporation (NASDAQ:FLDM). Levin Capital Strategies Limited Partnership holds 8.70M shares. Meeder Asset Mngmt Incorporated, Ohio-based fund reported 303 shares.

Since October 16, 2017, it had 13 insider purchases, and 0 sales for $3.57 million activity.

The stock of Fluidigm Corporation (NASDAQ:FLDM) is a huge mover today! The stock increased 10.57% or $0.76 during the last trading session, reaching $7.95. About 165,326 shares traded. Fluidigm Corporation (NASDAQ:FLDM) has declined 36.51% since February 15, 2017 and is downtrending. It has underperformed by 53.21% the S&P500.
The move comes after 6 months positive chart setup for the $307.25 million company. It was reported on Feb, 15 by We have $8.51 PT which if reached, will make NASDAQ:FLDM worth $21.51M more.

Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage

Among 5 analysts covering Fluidigm (NASDAQ:FLDM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Fluidigm had 22 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Neutral” rating by Piper Jaffray on Friday, August 7. The firm has “Hold” rating given on Sunday, August 9 by Mizuho. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Hold” rating by Piper Jaffray on Thursday, February 8. The firm has “Buy” rating given on Friday, August 5 by Mizuho. Piper Jaffray maintained Fluidigm Corporation (NASDAQ:FLDM) on Monday, September 4 with “Hold” rating. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Buy” rating by Deutsche Bank on Thursday, January 7. The firm earned “Hold” rating on Friday, August 4 by Cowen & Co. The firm earned “Hold” rating on Thursday, August 27 by Maxim Group. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, August 5. The firm earned “Neutral” rating on Friday, August 7 by Mizuho.

More recent Fluidigm Corporation (NASDAQ:FLDM) news were published by: which released: “Fluidigm to Participate in Upcoming Health Care Investor Conferences” on February 14, 2018. Also published the news titled: “Fluidigm Corp’s (FLDM) CEO Chris Linthwaite on Q4 2017 Results – Earnings Call …” on February 09, 2018.‘s news article titled: “Fluidigm Announces Fourth Quarter and Full Year 2017 Financial Results and …” with publication date: February 08, 2018 was also an interesting one.

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. The company has market cap of $307.25 million. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 systems; integrated fluidic circuits consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. It currently has negative earnings. The firm also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.